Related Experiment Videos
Immunologic approaches to antigen discovery for cancer vaccines
1Northwest Biotherapeutics, Inc., 2203 Airport Way South, Suite 200, Seattle, WA 98134, USA.
Abstract:
Since the early 1990s, scientists have identified an ever-expanding number of antigens to serve as targets for experimental cancer treatments, based on the stimulation of a patient's immune system. Using both immune cells and serum to screen potential candidates, several promising antigens are currently components of vaccines directed against a wide range of tumour types. These antigens vary in their tumour- and tissue-specificity. Their utility as a single reagent or as part of a multi-dimensional approach is as varied as the genes themselves. However, there are already reports indicating that the promise of evoking a clinically beneficial immune response, toward human tumours, is being fulfilled. In this review, we provide a summary of the current status of immunologic approaches to antigen discovery. We also discuss the need for additional, supportive data from non-immunologic techniques, as well as the progression of the preclinical process towards target validation.
Insights
Scientists are discovering new cancer antigens for immune system stimulation. These tumor antigens are key components of experimental cancer vaccines, showing promise for clinical benefits.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Since the early 1990s, numerous antigens have been identified as targets for experimental cancer treatments.
- These antigens stimulate a patient's immune system to fight cancer.
- Current research focuses on identifying tumor- and tissue-specific antigens.
Purpose of the Study:
- To review the current status of immunologic approaches to cancer antigen discovery.
- To discuss the need for non-immunologic data in target validation.
- To explore the progression of preclinical processes for cancer antigen development.
Main Methods:
- Screening potential cancer antigen candidates using immune cells and serum.
- Evaluating tumor antigens for their specificity and utility in cancer vaccines.
- Reviewing existing literature on immunologic and non-immunologic techniques for antigen discovery.
Main Results:
- Several promising tumor antigens have been identified and are components of cancer vaccines.
- These antigens exhibit varying degrees of tumor and tissue specificity.
- Evidence suggests that stimulating an immune response against human tumors can be clinically beneficial.
Conclusions:
- Immunologic approaches have led to promising cancer antigen discoveries for vaccine development.
- Additional non-immunologic data are crucial for validating these targets.
- The preclinical process for cancer antigen development is advancing towards target validation.